GLP-1 drugs like Ozempic and Wegovy, originally developed for diabetes, are increasingly used for weight loss. State Medicaid programs are debating whether to cover these drugs, citing potential health benefits and long-term cost savings. However, some researchers question whether they truly reduce healthcare costs over time. Do you think Medicaid should cover these drugs for weight loss?
